Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)
Market Currents

Biogen Idec (BIIB +2%) and Isis Pharmaceuticals (ISIS +2.8%) enter into an agreement to develop...

  • Friday, June 29, 2012, 1:08 PM ET
    Biogen Idec (BIIB +2%) and Isis Pharmaceuticals (ISIS +2.8%) enter into an agreement to develop and commercialize an antisense drug for the treatment of Steinert disease. Isis will receive an upfront payment of $12M and is responsible for the discovery of a lead drug candidate. In all, the deal could see Isis rake in more than $271M.
Track new comments on this story

This news story has 6 comments:

  •  
    Seems to be a beneficial and expanding relationship. Look for more ISIS partnership and pipeline news this year.
    29 Jun 2012, 01:29 PM Reply Like
  •  
    Is it true that ISIS could be very profitable just with 4 0r 5 deals like this one per year and then the ensuing royalties?.
    29 Jun 2012, 01:54 PM Reply Like
  •  
    Semiretired physician(General Surgeon)
    Longtime investor in ISIS
    29 Jun 2012, 01:54 PM Reply Like
  •  
    I'm a semi retired General Surgeon and a longtime fan(investor) of ISIS
    29 Jun 2012, 01:54 PM Reply Like
  •  
    As a former medical librarian, I am pleased to see a company doing good for patients resulting in profits for the investors as well.
    1 Jul 2012, 02:58 PM Reply Like
  •  
    You can follow a very good and active message board with all the moving Isis parts here.
    http://bit.ly/JC0uFl
    1 Jul 2012, 04:25 PM Reply Like
LATEST|
TODAY SO FAR|
YESTERDAY
Other date
DJIA (DIA) S&P 500 (SPY)

HEALTHCARE ETFs IN FOCUS

Latest Healthcare Articles
More Latest Articles »